Zacks Research Has Negative Estimate for BMY Q1 Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Investment analysts at Zacks Research dropped their Q1 2026 earnings per share estimates for shares of Bristol Myers Squibb in a report issued on Thursday, February 19th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings per share of $1.40 for the quarter, down from their previous estimate of $1.50. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s Q2 2026 earnings at $1.62 EPS, Q3 2026 earnings at $1.58 EPS, FY2026 earnings at $6.07 EPS, Q1 2027 earnings at $1.31 EPS, Q3 2027 earnings at $1.51 EPS, FY2027 earnings at $5.71 EPS and FY2028 earnings at $4.38 EPS.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same period in the previous year, the firm posted $1.67 earnings per share. The company’s revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS.

Other research analysts also recently issued research reports about the stock. Leerink Partners lifted their price objective on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. HSBC restated a “hold” rating and issued a $53.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Piper Sandler reaffirmed an “overweight” rating and set a $66.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a research report on Wednesday, January 28th. The Goldman Sachs Group reiterated a “neutral” rating and set a $57.00 price objective (up previously from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Finally, Guggenheim reissued a “buy” rating and issued a $72.00 price objective (up previously from $62.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Nine equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Hold” and an average price target of $60.19.

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock opened at $60.32 on Friday. The company has a market capitalization of $122.85 billion, a PE ratio of 17.49, a P/E/G ratio of 0.17 and a beta of 0.29. The company has a 50-day simple moving average of $56.05 and a two-hundred day simple moving average of $49.86. Bristol Myers Squibb has a one year low of $42.52 and a one year high of $63.33. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26.

Bristol Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is presently 73.04%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of BMY. Swiss RE Ltd. acquired a new position in Bristol Myers Squibb in the 4th quarter worth approximately $25,000. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at $25,000. Physician Wealth Advisors Inc. increased its stake in shares of Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 202 shares during the period. Harbor Capital Advisors Inc. raised its holdings in shares of Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 313 shares during the last quarter. Finally, EQ Wealth Advisors LLC acquired a new position in Bristol Myers Squibb during the fourth quarter valued at $32,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.